Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
There is a continuing need to educate clinicians about the differences in toxicity profiles between TKIs and the various strategies that are being evaluated in clinical trials to mitigate the risk of adverse events associated with TKI therapy for CML and MPN.
Category
  • Chronic Myelogenous Leukemia
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation